

6-12-2017

# Engineering Synthetic Antibody by Expanded Genetic Code

Elizabeth Batiuk

*Santa Clara University*, [ebatiuk@scu.edu](mailto:ebatiuk@scu.edu)

Tracy Nguyen

*Santa Clara University*, [t1nguyen@scu.edu](mailto:t1nguyen@scu.edu)

Casey Kiyohara

*Santa Clara University*, [ckiyohara@scu.edu](mailto:ckiyohara@scu.edu)

Follow this and additional works at: [http://scholarcommons.scu.edu/bioe\\_senior](http://scholarcommons.scu.edu/bioe_senior)



Part of the [Biomedical Engineering and Bioengineering Commons](#)

---

## Recommended Citation

Batiuk, Elizabeth; Nguyen, Tracy; and Kiyohara, Casey, "Engineering Synthetic Antibody by Expanded Genetic Code" (2017). *Bioengineering Senior Theses*. 60.

[http://scholarcommons.scu.edu/bioe\\_senior/60](http://scholarcommons.scu.edu/bioe_senior/60)

This Thesis is brought to you for free and open access by the Engineering Senior Theses at Scholar Commons. It has been accepted for inclusion in Bioengineering Senior Theses by an authorized administrator of Scholar Commons. For more information, please contact [rsccroggin@scu.edu](mailto:rsccroggin@scu.edu).

# SANTA CLARA UNIVERSITY

Department of Bioengineering

I HEREBY RECOMMEND THAT THE THESIS PREPARED  
UNDER MY SUPERVISION BY

Tracy Nguyen, Casey Kiyohara, Elizabeth Batiuk

ENTITLED

ENGINEERING SYNTHETIC ANTIBODY BY EXPANDED  
GENETIC CODE

BE ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS  
FOR THE DEGREE OF

**BACHELOR OF SCIENCE**  
IN  
**BIOENGINEERING**

Zhiwen Zhang  
Thesis Advisor

June 12, 2017  
date

Yulei Ye  
Department Chair

6/12/17  
date

# **Engineering Synthetic Antibody by Expanded Genetic Code**

By:

Tracy Nguyen, Casey Kiyohara, Elizabeth Batiuk

**Senior Design Project Report**

Submitted to

The Department of Bioengineering  
Of

SANTA CLARA UNIVERSITY

In Partial Fulfillment of the Requirements for the degree of  
Bachelor of Science in Bioengineering

Santa Clara, California

Spring 2017

# Engineering Synthetic Antibody by Expanded Genetic Code

Elizabeth Batiuk, Tracy Nguyen, Casey Kiyohara

Department of Bioengineering

Santa Clara University

2017

## **Abstract**

Antibodies are extensively used in research for diagnostic and therapeutic purposes because of their unrivaled specificity and biomarker binding strengths.<sup>1</sup> Currently, monoclonal antibodies are most commonly used because of their production consistency and purity.<sup>1</sup> However, there are significant ethical and economic challenges associated with producing monoclonal antibodies.<sup>1</sup> Synthetic antibodies provide a promising alternative to monoclonal antibodies in both clinical and research applications.<sup>2</sup>

Our proposed synthetic antibody system incorporates 3,4-dihydroxy-L-phenylalanine (L-DOPA), an unnatural amino acid used to increase binding affinity, into a peptide sequence specific for the prostate specific antigen (PSA), a biomarker for prostate cancer. This addition is predicted to give the synthetic antibody binding affinity and PSA specificity comparable to existing monoclonal antibodies while avoiding their drawbacks.<sup>3</sup> If successful, our system would replace monoclonal antibodies for PSA detection as well as be a promising model for developing countless other synthetic antibodies.

# **Acknowledgments**

Dr. Zhiwen (Jonathan) Zhang

Santa Clara University, School of Engineering

Santa Clara University, Department of Bioengineering

Santa Clara University, Undergraduate Programs Senior Design Project Fund

## Table of Contents

<b>Abstract.....</b>	<b>iii</b>
<b>Acknowledgments .....</b>	<b>iv</b>
<b>List of Figures.....</b>	<b>vii</b>
<b>Abbreviations .....</b>	<b>viii</b>
<b>Introduction.....</b>	<b>1</b>
<b>Background, Significance, &amp; Motivation .....</b>	<b>1</b>
<b>Literature Review .....</b>	<b>3</b>
<b>Critiques of Current Literatures and Technologies .....</b>	<b>6</b>
<b>Project Objectives.....</b>	<b>7</b>
<b>Overall Design.....</b>	<b>7</b>
<b>Milestones &amp; Expected Results.....</b>	<b>10</b>
<b>Team Management .....</b>	<b>11</b>
<b>Chapter 1: Vector Design &amp; Cloning.....</b>	<b>12</b>
<b>Introduction .....</b>	<b>12</b>
<b>Back-up Plan.....</b>	<b>12</b>
<b>Design Logic and Reasoning.....</b>	<b>12</b>
<b>Materials and Methods .....</b>	<b>14</b>
<b>Results.....</b>	<b>15</b>
<b>Discussion .....</b>	<b>17</b>
<b>Chapter 2: Protein Expression .....</b>	<b>18</b>
<b>Introduction .....</b>	<b>18</b>
<b>Back-up Plan.....</b>	<b>19</b>
<b>Materials and Methods .....</b>	<b>19</b>
<b>Results.....</b>	<b>21</b>
<b>Discussion .....</b>	<b>21</b>
<b>Chapter 3: Protein Purification .....</b>	<b>23</b>
<b>Introduction .....</b>	<b>23</b>

Back-up Plan .....	23
Materials and Methods .....	23
Results.....	24
Discussion .....	25
Chapter 4: Conclusion .....	26
Testing & Analysis.....	26
Summary and Future Applications.....	27
Chapter 5: Ethical Concerns.....	28
Chapter 6: Engineering Standards and Realistic Constraints .....	29
Economic .....	29
Ethical.....	29
Social.....	30
Manufacturability.....	30
Health & Safety.....	31
References .....	32
Appendix.....	34
Appendix A: pAC DHPheRS-6TRN plasmid map .....	34
Appendix B: Experimental Vector .....	35
Appendix C. Experimental Vector: pET28-P1+GFP+His Sequencing Information.....	36
Appendix D. Control Vector: pET28-P1+GFP+His Sequencing Information.....	41
Appendix E. Cloning Reactions.....	48
Appendix F. Project Expenses.....	50
Appendix G. Project Timeline.....	51

## List of Figures

Figure 1: Specific Antibody-Antigen Binding .....	1
Figure 2. Increased levels of PSA indicate prostate cancer .....	2
Figure 3. Synthetic Antibody Detection and Binding of PSA .....	8
Figure 4. Experimental and control nucleotide design sequence alignment .....	13
Figure 5. Step-by-step of double digestion of vector to insert peptide .....	13
Figure 6. 1% agarose gel for pET28b-GFP .....	15
Figure 7. Sequence Alignment of Experimental (Query) and Control (Sbjct) Vectors.....	16
Figure 8. Chromatograms. ....	17
Figure 9. Sequential co-transformation of pET28b+P1+GFP and pAC-DHPheRS-6TRN. ....	18
Figure 10. Transformed E. coli + pAC-DHPheRS-6TRN.....	21
Figure 11. Experimental (A), control (B), and no GFP (C) cultures.....	21
Figure 12. SDS-PAGE of purification.....	24



# Abbreviations

CIP: Calf Intestinal Phosphatase

*E. coli*: *Escherichia coli*

ELISA: Enzyme-linked Immunosorbent Assays

FPLC: Fast Protein Liquid Chromatography

GFP: Green Fluorescent Protein

6-His: Poly-histidine Amino Acid Motif

IPTG: Isopropyl  $\beta$ -D-1-thiogalactopyranoside

ITC: Isothermal Titration Calorimetry

kDA: kilo Dalton

Kan: Kanamycin

K<sub>d</sub>: Dissociation Equilibrium Constant

LB: Lysogeny Broth

L-DOPA: 1-3, 4-dihydroxyphenylalanine

MW: Molecular Weight

NEB: New England Biolabs

OD<sub>600</sub>: Optical Density at 600nm

PBS: Phosphate Buffered Saline

PMSF: Phenylmethane Sulfonyl Fluoride

PSA: Prostate Specific Antigen

P1: Peptide One

Rpm: Revolutions Per Minute

SDS-PAGE: Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis

TAG: Amber Stop codon

Tet: Tetracycline

tRNA: Transfer Ribonucleic Acid


UV: Ultraviolet

# Introduction

---

## Background, Significance, & Motivation


Antibodies are naturally produced by the immune system to fight off foreign invaders.<sup>1</sup> Because they are specific to a single antigen on a pathogen or infected cell and bind strongly to this antigen, immune cells are able to locate and destroy these target cells effectively (See Figure 1).<sup>1</sup> In order to take advantage of the naturally high strength and specificity of antibody-antigen interactions, scientific researchers have commercialized antibodies for diagnostic and therapeutic purposes.<sup>1</sup> Diagnostic applications include Western blots and ELISA, which detect the presence of specific proteins, antibodies, or antigens in a given sample.<sup>1</sup> Transducer-based assays are other diagnostic tools that use antibodies for a wide range of applications, including cancer and diabetes screening.<sup>4</sup> Therapeutic antibodies are used to treat autoimmune disorders, cardiovascular diseases, and types of cancer.<sup>5</sup>



**Figure 1: Specific Antibody-Antigen Binding**

One application of these commercial antibodies is prostate cancer detection. Prostate cancer is the second most common cancer among men. One in seven men will be diagnosed with prostate cancer in his lifetime.<sup>6</sup> Like most cancer, it is crucial to detect the cancer early, before it

metastasizes.<sup>6</sup> If detected early enough, 96% of diagnosed men will live another 15 years. There are two main methods of detecting prostate cancer.<sup>6</sup> One indication is an enlarged or abnormal prostate discovered during a digital rectal exam.<sup>6</sup> Another is the level of PSA in the blood.<sup>6</sup> As shown in Figure 2, a healthy prostate secretes a small amount of PSA.<sup>6</sup> However, a higher level of PSA in the blood is seen in those with prostate cancer.<sup>6</sup> During routine blood work, the amount of PSA can be detected using a monoclonal antibody.<sup>7</sup>



**Figure 2. Increased levels of PSA indicate prostate cancer.**

Monoclonal antibodies are the gold standard in research and medical applications because of their inherent consistency and purity.<sup>1</sup> However, disadvantages of using monoclonal antibodies include batch-to-batch variability, ethical concerns, and an expensive and lengthy production process.<sup>1</sup> Synthetic antibodies provide a promising alternative to monoclonal antibodies because they overcome many of the significant drawbacks of monoclonal antibodies while maintaining comparable function.<sup>8</sup>

This project focuses on the development of a synthetic antibody, produced in *E. coli*, using L-DOPA, an unnatural amino acid, incorporation for detection of prostate cancer. The antibody is specific for PSA, which can indicate prostate cancer at elevated levels.<sup>7</sup> This synthetic antibody

design offers comparable specificity and binding strength to the monoclonal antibody while also minimizing the drawbacks involved with production. If successful, this system would replace monoclonal antibodies for PSA detection, be a promising model for developing countless other synthetic antibodies, and contribute to the development of personalized medicine in the future.

## **Literature Review**

### *Design*

The basis of this project is a paper by Umeda et al. which details the incorporation of an unnatural amino acid, L-DOPA, to a peptide (TOP1), GFP reporter protein, and 6-His purification tag.<sup>3</sup> This system, with the exception of the peptide sequence specific for PSA, is the same as the proposed system of this project. The peptide of the synthetic antibody described in the paper is specific to the antigen Abelson tyrosine kinase (AbI).<sup>3</sup> Similarly, Therriault and Evans designed a system with a similar design to that of Umeda et al. that targets PSA.<sup>14</sup> Although these systems differ from the synthetic antibody in structure and target, the methods and protocols for unnatural amino acid incorporation and protein expression used in these papers will be a model and starting point for procedures used throughout this project.

### *Unnatural Amino Acids*

Unnatural amino acids are amino acids not used by ribosomes in cells to make proteins naturally.<sup>8</sup> They can have unique chemistry compared to natural amino acids and have therefore been proposed as a solution to the inherently weak binding strength between small peptides and larger proteins when incorporated into the peptide.<sup>3</sup> L-DOPA is the unnatural amino acid used by Umeda et al. to increase the binding strength of a small peptide to a larger protein.<sup>3</sup> The unnatural amino acid performs a redox reaction with a nearby nucleophile in the presence of sodium periodate, creating a strong covalent bond.<sup>3</sup> L-DOPA is particularly useful for unnatural amino acid incorporation into a recombinant protein because it is orthogonal to natural amino acids, which ensures correct translation of the peptide including incorporation of L-DOPA.<sup>3</sup> L-DOPA will therefore be used in this project to increase the binding strength of the synthetic antibody to PSA using a covalent bond.

Unnatural amino acids such as L-DOPA can be incorporated into the peptide by introducing into the cell a mutant tRNA and tRNA synthetase, which are designed to recognize the amber stop codon (TAG/UAG) on mRNA and incorporate the unnatural amino acid at that location on the growing peptide.<sup>8</sup> The amber stop codon is used because of the three stop codons used naturally, it is the least frequently used in *E. coli* (7%) and is rarely used on essential proteins.<sup>8</sup> Using this stop codon minimizes the likelihood of unnatural amino acid incorporation disrupting normal cell function and killing the cell.<sup>8</sup> The amber stop codon will therefore be used to incorporate L-DOPA into this synthetic antibody. The pAC-DHPheRS-6TRN plasmid used by Therriault and Evans contains the genetic code for the mutant tRNA and tRNA synthetase, and will be used in this project.<sup>14</sup>

The use of unnatural amino acid incorporation in any protein, peptide, or small molecule system is a cutting edge technology.<sup>9</sup> Researchers and pharmaceutical companies have begun using this technology to engineer antibodies.<sup>9</sup> As this process is developed, they experience many obstacles to synthetic antibody expression and manufacturing.<sup>9</sup> These production challenges will be important considerations in this project as it attempts to develop an accessible and viable product for companies.<sup>9</sup> The solutions other researchers discovered to overcome these challenges will be helpful for this project.<sup>9</sup>

One issue faced by researchers incorporating unnatural amino acids at the carboxy terminus of a gene is truncation of the protein.<sup>10</sup> It is very difficult to separate the truncated protein from the fully-translated protein, and a group of researchers overcame this issue by attaching an intein protein.<sup>10</sup> The intein protein is attached with a tag after the unnatural amino acid amber stop codon and promotes full translation of the protein.<sup>10</sup> This method achieves higher purity and function and avoids a commonly encountered problem when purifying unnatural amino acids.<sup>10</sup> This method would be considered for this project if truncated protein expression becomes an issue.

### *Methods and Procedures*

One major benefit of this project is avoiding using animals to produce antibodies.<sup>8</sup> Instead, *E. coli* will be used to produce comparable antibodies.<sup>8</sup> *E. coli* are commonly used for protein

production because introducing exogenous recombinant DNA, such as the plasmid for the synthetic antibody, into them is an established process.<sup>18</sup> In addition, by using *E. coli*, the synthetic antibody production is able to avoid the ethical concerns of using and killing animals.<sup>11</sup> The use of *E. coli* also limits economic cost, as scaling up production in *E. coli* is fast due to the short doubling time of the cells, allowing for high density cultures in bioreactors with simple growing conditions, rather than requiring large animal facilities.<sup>18</sup> These characteristics of *E. coli* as a production platform therefore make it ideal for use in this project.

However, since there are big differences between mammalian and *E. coli* protein production, it is important to understand the drawbacks to using *E. coli*.<sup>8</sup> These include susceptibility to genetic mutations as well as the lack of ability to perform post-translational modifications.<sup>8</sup> Since the synthetic antibody used in this project will only be 45 nucleotides, sequencing will be used to verify the DNA sequence is correct. The synthetic antibody also does not require any post-translational modifications because of its length, making *E. coli* a simple and effective expression platform.

There are three published methods of protein expression with L-DOPA incorporation into peptides with similar designs to this project's synthetic antibody.<sup>3,16,17</sup> They vary by inducer, incorporation time, and induction and growth times. To optimize expression and yield of the synthetic antibody, this project will perform separate but simultaneous experiments using each of these three methods to identify and develop the most effective expression protocol.

### *Prostate Cancer Detection*

After successfully producing the synthetic antibody, one important aspect of this project will be assessing whether it is truly comparable to monoclonal antibodies for both diagnostic and therapeutic applications. Researchers have found that the  $K_d$  of PSA to immobilized monoclonal antibody on a diagnostic chip is  $1.1 \pm 0.2$  nM, giving us a metric by which to assess the binding affinity of our system.<sup>7</sup> In addition, researchers also identified a concentration of PSA (2.6 ng/mL to 4.0 ng/mL) which detects the presence of small prostate cancer without over-diagnosing patients.<sup>7</sup> This range is a design specification necessary for the synthetic antibody to

achieve target specificity and sensitivity to PSA. Together, these results will determine whether the synthetic antibody is a viable alternative to monoclonal antibodies.

## **Critiques of Current Literatures and Technologies**

Monoclonal antibodies are extensively used in research.<sup>1</sup> However, there are many disadvantages of using monoclonal antibodies, including the use of animals, a long manufacturing process and high production costs.<sup>1</sup> Antibody production is stimulated in animal immune systems by injecting them with the target antigen.<sup>5</sup> Once the animal's B-cells start producing antibodies specific to the antigen, the B-cells are harvested.<sup>5</sup> In order to scale up antibody production, the B-cells are combined with an immortal cell line.<sup>5</sup> The resulting mass production of antibodies is homogenous and pure.<sup>5</sup> This entire process can take months to accomplish and is associated with significant production costs.<sup>5</sup> As a result, this leads to increased medical expenses for consumers and limits accessibility to these technologies.<sup>11</sup> In addition, the use of animals raises many ethical dilemmas and therefore is highly debated in scientific research.<sup>11</sup>

The primary alternative to monoclonal antibodies is polyclonal antibodies, which have the same structure and specificity as monoclonal antibodies while requiring less time, skill, and money to produce.<sup>1</sup> However, because they still are produced in animals, they have the same ethical concerns as monoclonal antibodies.<sup>1</sup> In addition, polyclonal antibodies derive from several different animals and B cell lines at different time points, resulting in batch-to-batch variation not present in monoclonal antibodies, which stem from a single cell line and are therefore more consistent.<sup>1</sup>

Among the other alternatives to monoclonal antibodies scientists are currently developing is protein scaffolds.<sup>12</sup> Protein scaffolds have a general protein framework with specific peptides or amino acids, which give them specificity to a target, incorporated in them.<sup>12</sup> These scaffolds can be diverse in size, folding, and method of interaction with their targets, giving them more flexibility than antibodies, which have a constant structure.<sup>12</sup> However, because there is very little data on their immunogenicity and degradability in biological fluids, their potential applications are currently limited.<sup>12</sup>

Another alternative to monoclonal antibodies currently being explored is aptamers.<sup>13</sup> Aptamers are strands of DNA or RNA which are selected from large libraries to be specific to a certain target.<sup>13</sup> Because they involve no animal use, they avoid the ethical issues of monoclonal antibodies.<sup>13</sup> In addition, because they are made of DNA or RNA, they are more stable than antibodies when being stored.<sup>13</sup> However, aptamers are known to degrade quickly when exposed to nucleases in biological fluid, limiting their potential applications, particularly for therapeutics.<sup>13</sup>


## **Project Objectives**

Based on the strengths and drawbacks of monoclonal antibodies, the overall goal of this project was established to be designing an alternative that maintained the strengths of monoclonal antibodies while avoiding their drawbacks as much as possible. The final project objective was to develop a cost-effective, ethical alternative to monoclonal antibodies that is easier and faster to manufacture with comparable quality: specificity, sensitivity, and binding strength.

## **Overall Design**

To meet the project objectives, a synthetic antibody produced in *E. coli* was designed. By being produced in *E. coli*, the synthetic antibody has a lower cost, shorter, and more ethical production process than that of monoclonal antibodies.<sup>5,11</sup> The physical design of the synthetic antibody contains four components: peptide, L-DOPA unnatural amino acid, GFP reporter protein, and 6-His purification tag (See Figure 3).





**Figure 3. Synthetic Antibody Detection and Binding of PSA.**

Components of the synthetic antibody include peptide (red), L-DOPA unnatural amino acid (black/red), green fluorescent protein (green), 6-His tag (purple). Exposure of synthetic antibody-PSA complex to sodium periodate (detection) allows for formation of a covalent bond (pink) between them.

The 15-amino-acid experimental peptide was designed by a previous Senior Design group, Therriault and Evans.<sup>14</sup> Using open source software developed by University of California, San Francisco, called Chimera, a library of peptides was screened using several parameters.<sup>14</sup> These parameters include electrostatic interactions and predicted binding affinity that were determined using the known active site where a commercially available monoclonal PSA antibody binds to PSA.<sup>14</sup> The top peptide candidate that was screened was selected as the experimental peptide for the design.<sup>14</sup> The peptide therefore is predicted to give the synthetic antibody high specificity to PSA.<sup>14</sup>

The unnatural amino acid, L-DOPA, was added to the end of the peptide sequence. As discussed in the literature review, this unnatural amino acid is capable of performing a redox reaction that creates a covalent bond when exposed to sodium periodate.<sup>3</sup> When incorporated into the synthetic antibody, this covalent bond is expected to form between the synthetic antibody and PSA once the peptide has specifically targeted the active site of PSA and sodium periodate is added.<sup>3</sup> This covalent bond greatly increases the binding strength of the synthetic antibody to PSA.<sup>3</sup> In order to incorporate this unnatural amino acid, a plasmid designed by Wang et al.,

pAC-DHPheRS-6TRN, will be transformed into the *E. coli* with the synthetic antibody plasmid.<sup>17</sup> This plasmid contains the genetic code for the mutant tRNA and tRNA synthetase necessary for unnatural amino acid incorporation.<sup>17</sup>

GFP was added to the synthetic antibody sequence after the unnatural amino acid. GFP is a commonly used reporter protein in research applications because of its simple visualization process requiring only UV light.<sup>19</sup> It therefore is used to visualize when and how much synthetic antibody is present during detection. GFP's straightforward visualization process was also taken advantage of to verify synthetic antibody expression, as its characteristic green fluorescence is visible in *E. coli* correctly producing the synthetic antibody.

The final component of the synthetic antibody, the 6-His tag, was a sequence of six consecutive histidines at the end of the synthetic antibody sequence. This 6-His sequence is well-established in the scientific community because its unlikelihood of occurring naturally in another *E. coli* protein makes it unique to the protein of interest and therefore ideal for targeting in protein purification.<sup>20</sup> This sequence therefore allows the synthetic antibody to be purified from the *E. coli* using affinity chromatography that targets this 6-His tag.

The synthetic antibody sequence was designed so that the ribosomes in the *E. coli* would first translate the peptide, followed sequentially by L-DOPA, GFP, and the 6-His tag. This design allows the ribosome to incorporate the unnatural amino acid, which stresses the ribosome more than natural amino acid incorporation, before translating the long GFP sequence.<sup>21</sup> It has been hypothesized that translating GFP stresses the ribosome because of its length, and therefore makes the ribosome more prone to translation errors.<sup>21</sup> Because of the expected crucial nature of the unnatural amino acid to the binding strength, and therefore effectiveness, of the synthetic antibody, the antibody was designed to minimize the chance of error in unnatural amino acid incorporation caused by ribosomal stress.

The synthetic antibody sequence was cloned into the pET-28b vector, which then was transformed into TOP10 competent *E. coli* cells. The pET-28b vector includes a lac operon and T7 promoter that allow for regulated expression.<sup>14</sup> It also includes a Kan resistance gene which

allows for selection of *E. coli* successfully transformed with this vector.<sup>14</sup> Co-transformed into the *E. coli* was the second plasmid, pAC-DHPheRS-6TRN (See Appendix A). This plasmid contains a Tet resistance gene used for selection of *E. coli* that have been successfully transformed with this second plasmid.<sup>14</sup> Therefore, cells were grown in the presence of both Kan and Tet in order to select for cells which have been successfully transformed with both plasmids.

## **Milestones & Expected Results**

The first milestone of the project is correct plasmid design. This plasmid provides the *E. coli* with the DNA sequence necessary to successfully produce the synthetic antibody. The final design must incorporate the sequence for all four components of the synthetic antibody adjacent to a promoter in the pET-28b vector to allow the *E. coli* to produce the synthetic antibody (See Appendix B).

The second milestone of the project is successful cloning and transformation. Here, the complete synthetic antibody sequence must be incorporated into the pET-28b vector at the correct location so that the cells transformed with these plasmids will be able to produce the synthetic antibody. The *E. coli* must then successfully be transformed with this plasmid and the pAC-DHPheRS-6TRN plasmid in order to begin producing the synthetic antibody.

Once the *E. coli* have been successfully transformed with the two plasmids, the third milestone of the project is successful expression of the synthetic antibody by *E. coli*. As mentioned in the literature review, there are several previously established methods of expression of proteins similar to that designed in this project. All were performed and tested while developing a successful expression protocol for the synthetic antibody.

After confirming expression, the next milestone is successful purification of the synthetic antibody. In order to reach a high standard of purity that is comparable to that of monoclonal antibodies, the synthetic antibody must be purified from all other proteins and other materials within the *E. coli* which is producing it. The effectiveness of the purification must be tested, optimized, and ultimately confirmed to ensure this high level of purity.

The final milestone of the project is testing of the synthetic antibody. In order to be comparable to monoclonal antibodies, and therefore a viable alternative, the synthetic antibody must either meet or exceed the standards of binding strength, specificity, and sensitivity set by monoclonal antibodies. As described in the literature review, these standards for the anti-PSA monoclonal antibody are well established, and therefore can be used to test and confirm the efficacy of the synthetic antibody.

## **Team Management**

To maintain accountability and efficiency throughout the project, various responsibilities were delegated among the team. Tracy is the liaison with the School of Engineering, handles team's finances, and acts as scribe during team and advisory meetings. She is also responsible for ensuring any deadlines are met. Elizabeth coordinates both meeting and laboratory scheduling for team and facilitates communications with the advisor, Dr. Zhang. Casey supervises all writing and editing for the final report and communicates with industry contacts. The laboratory work, report writing, and presentation development was divided equally among team members.

# Chapter 1: Vector Design & Cloning

---

## Introduction

In designing the cloning of the synthetic antibody sequence into the vector, the synthetic antibody sequence must incorporate restriction sites that match ones at specific sites in the vector in order to localize the synthetic antibody sequence near the promoter.

Because there is a Kan resistance gene included in the vector, it is expected that cells which have been successfully transformed with the pET-28b vector will be resistant to Kan. Of the cells which are resistant to Kan, some will be selected for DNA sequencing, which will confirm that the cloning of the synthetic antibody sequence into the vector was successful.

## Back-up Plan

If cloning is not accomplished in the allotted time, the oligonucleotide sequences will be sent to a company to be cloned into pET28b.

## Design Logic and Reasoning

### *Peptide Design*

Two sets of forward and reverse single-stranded oligonucleotides of the peptide fragments coding for the synthetic antibody and negative control were purchased from BioBasic. One set of oligonucleotides has the amber stop codon (TAG) sequence which would allow for successful unnatural amino acid incorporation while the other set has a codon for alanine (GCG) in place of the TAG sequence, serving as the negative control (See Figure 4). This negative control, which besides this one amino acid is identical to the experimental synthetic antibody, will be used during the testing phase to confirm that L-DOPA has been incorporated and is increasing the binding strength of the synthetic antibody as expected. The forward and reverse oligos were constructed to have 17 overlapping nucleotides to optimize annealing efficiency and specificity. Each set of oligonucleotides (experimental (TAG) and control (GCG)) were annealed together to form two double-stranded fragments. Then the double-stranded fragments were extended into


complete inserts through a klenow reaction. The klenow reaction was selected over a PCR reaction due to its high efficiency of extension for short fragments such as this peptide, which is less than 150 base pairs.

Experimental	1 ATGTGCGTGGCGTATTGCATTGAACATCATTGCTGGACCTGCTAG	45
Control	1 ATGTGCGTGGCGTATTGCATTGAACATCATTGCTGGACCTGCGCG	45

**Figure 4. Experimental and control nucleotide design sequence alignment.** Experimental sequence is specific for PSA and contains 3' TAG codon for L-DOPA incorporation. Control peptide serves as a negative control for L-DOPA incorporation and contains a codon for alanine.

### *Expression Vector Selection*

pET28b-GFP was selected as the expression vector because it contains an enhanced GFP. It also contains a 6-His that will be used during protein purification by affinity chromatography. The oligonucleotides were cloned on the 3' end of the T7 promoter and 5' of the 6-His and GFP (See Figure 5).



**Figure 5. Step-by-step of double digestion of vector to insert peptide.**

## Materials and Methods


### *pET28b-PI-TAG-GFP Vector Construction*

The peptide predicted to be specific for PSA was selected through an *in silico* screen as described by Therriault and Evans.<sup>1</sup> Oligonucleotides containing experimental or control peptides, restriction sites, and flanking sequences were ordered as two overlapping fragments (BioBasic), annealed, and extended using the large polymerase I, large (klenow) fragment for 15 minutes at 25°C (NEB, See Appendix E Table 1). Products were run on a 2% agarose gel for verification. Oligonucleotides were purified by QIAquick PCR Purification Kit (Qiagen) and double digested with restriction endonucleases EcoRI-HF and XbaI (NEB) for 10 hours at 37°C (See Appendix E Table 2). Products were purified (Qiagen) prior to ligation.

pET28b-GFP contains a 6-His and genes for Kan resistance and GFP. 5 mL cultures were grown in LB (Teknova) with 50 µg/mL Kan (Teknova) and plasmids were purified by QIAprep Spin Miniprep Kit (Qiagen). Plasmids were double digested for four hours at 37°C (See Appendix E Table 3) and run on 1% agarose gel, gel extracted, and purified using the QIAquick Gel Extraction Kit (Qiagen). 5' DNA ends were dephosphorylated using CIP (NEB, See Appendix E Table 4) and subsequently purified (Qiagen) prior to ligation in order to minimize self-ligation of the vector without incorporation of the insert.

Ligations (one set for each the control and experimental oligonucleotides) were performed using T4 DNA Ligase (Promega) at 1:1, 1:2 and 1:10 ratios of pET28b-GFP:oligonucleotide (See Appendix E Table 5) and transformed into TSS TOP10 chemically competent cells (as described in Chung et al.) before being plated onto LB-agar (MP Biomedicals LLC) plates containing 50 µg/mL Kan.<sup>15</sup> Colonies were picked and grown in 5 mL LB + 50 µg/mL Kan cultures. DNA was purified (Qiagen) and sequenced (Sequetech) using the T7 primer.

## Results



**Figure 6.** 1% agarose gel for pET28b-GFP vector cut (left two bands) and uncut (right band) by EcoRI-HF and Xba1 restriction enzymes. Visualized using Fisher Scientific Transilluminator and 0.5 µg/mL EtBr. Ladder (far right) was Quick-load 1kb DNA ladder (NEB).




Sequence ID: Query\_70297 Length: 777 Number of Matches: 1

Range 1: 1 to 777 [Graphics](#) [Next Match](#) [Previous Match](#)

Score	Expect	Identities	Gaps	Strand
1424 bits(771)	0.0	775/777(99%)	0/777(0%)	Plus/Plus
Query 1	AAGCTTTTGTAGAGCTCATCCATGCCATGTGTAATCCCAGCAGCAGTTACAAACTCAAG	60		
Sbjct 1	AAGCTTTTGTAGAGCTCATCCATGCCATGTGTAATCCCAGCAGCAGTTACAAACTCAAG	60		
Query 61	AAGGACCATGTGGTCACGCTTTTCGTTGGGATCTTTCGAAAGGGCAGATTGTGTCGACAG	120		
Sbjct 61	AAGGACCATGTGGTCACGCTTTTCGTTGGGATCTTTCGAAAGGGCAGATTGTGTCGACAG	120		
Query 121	GTAATGGTTGTCTGGTAAAAGGACAGGGCCATCGCCAATTGGAGTATTTTGTGATAATG	180		
Sbjct 121	GTAATGGTTGTCTGGTAAAAGGACAGGGCCATCGCCAATTGGAGTATTTTGTGATAATG	180		
Query 181	GTCTGCTAGTTGAACGGATCCATCTTCAATGTTGTGGCGAATTTTGAAAGTTAGCTTTGAT	240		
Sbjct 181	GTCTGCTAGTTGAACGGATCCATCTTCAATGTTGTGGCGAATTTTGAAAGTTAGCTTTGAT	240		
Query 241	TCCATTCTTTTGTGTTGCTGCCGTGATGTATACATTGTGTGAGTTATAGTTGTAAGTCTGAG	300		
Sbjct 241	TCCATTCTTTTGTGTTGCTGCCGTGATGTATACATTGTGTGAGTTATAGTTGTAAGTCTGAG	300		
Query 301	TTTGTGTCCGAGAAATGTTTCATCTTCTTTAAATCAATACCTTTTAAGTTCGATACGATT	360		
Sbjct 301	TTTGTGTCCGAGAAATGTTTCATCTTCTTTAAATCAATACCTTTTAAGTTCGATACGATT	360		
Query 361	AACAAGGGTATCACCTTCAAACTTGACTTCAGCACGCGTCTTGTAGTTCCCGTCATCTTT	420		
Sbjct 361	AACAAGGGTATCACCTTCAAACTTGACTTCAGCACGCGTCTTGTAGTTCCCGTCATCTTT	420		
Query 421	GAAAGATATAGTGCCTTCCTGTACATAACCTTCGGGCATGGCACTCTTGAAAAAGTCATG	480		
Sbjct 421	GAAAGATATAGTGCCTTCCTGTACATAACCTTCGGGCATGGCACTCTTGAAAAAGTCATG	480		
Query 481	CCGTTTCATATGATCCGGATAACGGGAAAAGCATTGAACACCATAAGAGAAAAGTAGTGAC	540		
Sbjct 481	CCGTTTCATATGATCCGGATAACGGGAAAAGCATTGAACACCATAAGAGAAAAGTAGTGAC	540		
Query 541	AAGTGTGGCCATGGAACAGGTAGTTTTCAGTAGTGCAAAATAAATTTAAGGGTAAGTTT	600		
Sbjct 541	AAGTGTGGCCATGGAACAGGTAGTTTTCAGTAGTGCAAAATAAATTTAAGGGTAAGTTT	600		
Query 601	TCCGTATGTTGCATCACCTTCACCTCTCCACTGACAGAAAATTTGTGCCATTAAACATC	660		
Sbjct 601	TCCGTATGTTGCATCACCTTCACCTCTCCACTGACAGAAAATTTGTGCCATTAAACATC	660		
Query 661	ACCATCTAATTCAACAAGAATTGGGACAACCTCAGTGAAAAGTTCTTCTCCTTTACTCAT	720		
Sbjct 661	ACCATCTAATTCAACAAGAATTGGGACAACCTCAGTGAAAAGTTCTTCTCCTTTACTCAT	720		
Query 721	GAATTCCTAGCAGGTCCAGCAATGATGTTCAATGCAATACGCCACGCACATTCTAGA	777		
Sbjct 721	GAATTCCTAGCAGGTCCAGCAATGATGTTCAATGCAATACGCCACGCACATTCTAGA	777		

**Figure 7. Sequence Alignment of Experimental (Query) and Control (Sbjct) Vectors.** Highlighted in red is the one amino acid difference between the two sequences.



**Figure 8. Chromatograms of Experimental (A) and Control (B) sequences at location of the amino acid difference.**

## Discussion


As seen in Figure 6, the vector was successfully double digested, however after sending the vectors to sequencing after cloning, the vectors were confirmed to have self-ligated instead of incorporating the peptide and L-DOPA. Varied time and order of digestion, and time of CIP reaction were performed. Unfortunately, due to time constraints, the designed vectors (one for control and one for experimental) were constructed at Epoch Life Science, Inc (Missouri City, TX). The vectors were sequenced and results are shown in Appendix C and Appendix D. Figure 7 shows the nucleotide alignment between the experimental and control vector sequence to verify they are correct and differ at the last codon of the peptide. Figure 8 shows the chromatogram of both the experiment and control peptides. The little background noise and clean peaks show the clones are correct and pure. The confidence that the vectors are pure and accurate is necessary before moving on to the next step of the project, synthetic and control antibody expression.

## Chapter 2: Protein Expression

---

### Introduction

In order to maximize efficiency of transformation, a stepwise transformation was performed, with cells successfully transformed with one plasmid then being made competent before being transformed with the second plasmid (See Figure 9). The pAC-DHPheRS-6TRN plasmid was transformed into *E. coli* first to increase transformation efficiency and minimize toxicity concerns caused by the mutant tRNA and tRNA synthetase. In addition, transformation of the pAC-DHPheRS-6TRN plasmid first allows for the potential future creation of a commercialized kit, containing competent cells into which a plasmid for any synthetic antibody containing L-DOPA can be transformed and immediately expressed.



**Figure 9. Sequential co-transformation of pET28b+P1+GFP and pAC-DHPheRS-6TRN**

In this step, confirmation of successful expression is performed by taking advantage of the design of the synthetic antibody. Because the design includes GFP, cells which are successfully producing synthetic antibody are expected to have a visual green fluorescence in the culture. Therefore, during expression of the synthetic antibody, the *E. coli* cultures were observed under UV light to confirm that there is this indicative green fluorescence.

## Back-up Plan

Although there are a few different aspects of expression where issues may arise, the methods of this project were designed to minimize those risks. In order to ensure expression, three different established L-DOPA protein expression methods were separately used to optimize yield and expression.<sup>3,16,17</sup> Since L-DOPA is easily oxidized, the pH was carefully controlled during expression. As discussed previously, expression of proteins with unnatural amino acids can result in truncated protein. Since GFP is at the carboxy terminus of the synthetic antibody, a truncated synthetic antibody would not fluoresce during expression. An intein protein could be attached to minimize truncation.<sup>10</sup> If these issues or others are experienced and not resolved in a timely manner, the experimental and control synthetic vectors will be sent to a company to be expressed.

## Materials and Methods

### *pAC-DHPheRS-6TRN Competent Cell Preparation*

pAC-DHPheRS-6TRN contains genes for the mutant tRNA and mutant tRNA synthetase as well as the Tet resistance gene. pAC-DHPheRS-6TRN was transformed into calcium chloride competent TOP10 *E. coli* cells using a high efficiency chemical transformation protocol (NEB). Cells were plated on LB-agar + 10 µg/mL Tet (Teknova). A single colony was picked and grown in LB broth + 10 µg/mL Tet and a glycerol stock was prepared. Chemically competent cells from this glycerol stock were made using the TSS protocol.<sup>15</sup>

### *Co-Transformation of pET28b-PI-TAG-GFP*

5 mL cultures of pET28b-PI-TAG-GFP and pET28b-PI-GCG-GFP (Epoch Life Science, Inc) were grown overnight before plasmids were purified (Qiagen) and transformed into pAC-DHPheRS-6TRN TOP10 competent *E. coli* cells and plated on LB-agar + 30 µg/mL Kan + 25 µg/mL Tet plates.

### *Antibody Expression Protocol #1*

This method was adapted from Zhang et al.<sup>16</sup> Co-transformed colonies (4 from TAG, 4 from GCG) were picked from LB-agar (Teknova, MP Biomedicals LLC) plates and grown in 2.0 mL

LB + 30 µg/mL Tet and 60 µg/mL Kan, shaking in the dark at 37°C overnight. 25% glycerol stocks were made for each cell line and stored at -80°C. 500 µL of overnight culture was added to 125 mL of M9 Medium Broth (Amresco) with 30 µg/mL Kan + 25 µg/mL Tet and 1 mM L-DOPA (Sigma-Aldrich) and grown in the dark in a shaking incubator at 37°C until OD<sub>600</sub> reached 0.5. The pH of the culture was maintained at pH 6.5 during growth. At OD<sub>600</sub> 0.5, 0.2% L-Arabinose (Sigma-Aldrich) was added and cultures were grown for 4 hours at 37°C. Cultures were harvested by centrifuge at 5,000 x g for 11 minutes at 4°C, supernatant was decanted and pellets were stored at -80°C.

#### *Antibody Expression Protocol #2*

This method was adapted from Wang et al.<sup>17</sup> Co-transformed colonies (4 from TAG, 4 from GCG) were picked from LB-agar plates and grown in 2.0 mL LB + 30 µg/mL Tet and 60 µg/mL Kan, shaking in the dark at 37°C overnight. 25% glycerol stocks were made for each cell line and stored at -80°C. 500 µL of overnight culture was added to 125 mL of M9 Medium Broth with 30 µg/mL Kan + 25 µg/mL Tet and 1 mM L-DOPA (Sigma-Aldrich) and grown in the dark in a shaking incubator at 37°C until OD<sub>600</sub> reached 0.5. The pH of the culture was maintained at pH 6.5 during growth. At OD<sub>600</sub> 0.5, 1 mM IPTG was added and cultures were grown for 5 hours at 37°C. Cultures were harvested by centrifuge at 5,000 x g for 11 minutes at 4°C, supernatant was decanted and pellets were stored at -80°C.


#### *Antibody Expression Protocol #3*

This method was adapted from Umeda et al.<sup>3</sup> Co-transformed colonies (4 from TAG, 4 from GCG) were picked from LB-agar plates and grown in 2.0 mL LB + 30 µg/mL Tet and 60 µg/mL Kan, shaking in the dark at 37°C overnight. 25% glycerol stocks were made for each cell line and stored at -80°C. 500 uL of overnight culture was added to 125 mL of M9 Medium Broth with 30 µg/mL Kan + 25 µg/mL Tet and grown in the dark in a shaking incubator, at 37°C until OD<sub>600</sub> reached 0.6. During this time, the pH of the culture was maintained at pH 6.5. At OD<sub>600</sub> 0.6, 1 mM IPTG was added to the cultures, which then were incubated at 30°C for 6 hours. Cultures


were viewed after 4 hours using a Fisher Scientific Transilluminator. Cultures were harvested by centrifuge at 5,000 x g for 11 minutes at 4°C, supernatant was decanted and pellets were stored at -80°C.

## Results

### *Co-Transformation of pET28b+PI+TAG and pAC-DHPheRS-6TRN*



**Figure 10.** Transformed *E. coli* + pAC-DHPheRS-6TRN plated on LB + agar + 10 µg/mL Tet+ 50 µg/mL Kan + 0.2% arabinose. TOP10 *E. coli* + pAC-DHPheRS-6TRN transformed with experimental synthetic antibody plasmid (A), control synthetic antibody plasmid (B), no plasmid (C), plasmid with no synthetic antibody (D).



**Figure 11.** Experimental (A), control (B), and no GFP (C) cultures using antibody expression protocol #3 visualized under UV light after 4 hours of synthetic antibody expression.

## Discussion

As shown in Figure 10, the co-transformation of pET28b+PI+TAG and pET28b+PI+GCG (control) into TOP10 competent cells containing pAC-DHPheRS-6TRN was successful. Plates C and D serve as negative controls. Plate C was plated with cells transformed with water and plate

D was plated with cells transformed with a plasmid without Tet resistance, a quality control for the plates.

For the cultures using expression protocol #3, the cultures were placed in UW light 4 hours after induction of synthetic antibody production with IPTG (Figure 11). Compared to the culture with cells not producing the synthetic antibody, which therefore were not producing GFP, the experimental and control cultures had a distinct green color under the UV, indicating that they were producing GFP and therefore the synthetic antibody. These results indicate successful expression of the synthetic antibody within the *E. coli* cells.

## Chapter 3: Protein Purification

---

### Introduction

Before testing the functionality of the synthetic antibodies, they must first be purified. This was done by manual affinity chromatography using 6-His. After lysing the cells, the proteins were separated and passed through a column containing Ni-NTA beads. Only the synthetic antibody will bind to the beads allowing for the other proteins to be removed. The synthetic antibody was then eluted as a pure sample from the beads.

### Back-up Plan

Although manual affinity chromatography is a well-defined purification procedure, if any issues arise, FPLC will be used. This automated process produces pure and large quantities of proteins. However, it would be time consuming to troubleshoot and learn how to use this machine. Purification can also be contracted out to a company if necessary.

### Materials and Methods

A separate purification was performed for each individual cell type and growing condition. *E. coli* pellets were thawed in a hot water bath for approximately 10 minutes. Each pellet was then resuspended in 5 mL of lysis buffer (PBS + 1 mg/mL lysozyme + 0.5 mM PMSF + 10 mM imidazole) and left on ice for 20 minutes. The cells were then sonicated 6 times at 30% alternating between 6 seconds on and 6 seconds off. The lysate was then centrifuged at 4°C and 16,000 rpm for 40 minutes. 1 mL sample of the supernatant was taken and stored in -20°C.

While centrifuging, one set of HisPur™ Ni-NTA beads (Thermo Fisher Scientific) specific to the 6-His tag was prepared for each culture by resuspending 125 µL of the beads (1:1000 ratio of volume of beads:volume of initial culture) in 5 mL of PBS + 25 mM imidazole before being centrifuged for 4 minutes at 2000 rpm. After pouring out the supernatant, this process was repeated 4 times.



The supernatant of the centrifuged lysate solutions was then used to resuspend the Ni-NTA beads (one culture per set of beads). Binding of the proteins to the beads was then done by rocking the resuspended beads at 4°C for 1 hour before centrifuging them for 4 minutes at 2000 rpm at 4°C. 1 mL of the flow-through after binding was then sampled and the rest was discarded. The beads were then washed 5 times. In these wash steps, the beads were resuspended in PBS + 25 mM imidazole wash buffer, rocked for 20 minutes at 4°C, then centrifuged at 2000 rpm at 4°C for 4 minutes before the supernatant was sampled and discarded.

For elution, the beads were resuspended in 200 µL of PBS + 250 mM imidazole, rocked for 20 minutes, and centrifuged at 2000 rpm for 4 minutes. The supernatant, which ideally contains the target protein, was then extracted and stored at -20°C. Two elution steps were performed for each culture.

Samples of lysate, flow-through, initial wash step, and elution for each purification were run on a SDS-PAGE (Genscript) at 120 volts for 60 minutes. Gels were visualized and imaged using LabSafe GEL Blue (G-Biosciences).

## Results



**Figure 12. SDS-PAGE of purification** Left image shows synthetic antibody and right shows control antibody. Lane one is PageRuler Prestained Protein Ladder (ThermoFisher Scientific). Lane two is sample of supernatant after cells were lysed and centrifuged. Lane three is flow-through sample after binding to column. Lane four is sample after first wash is performed. Lane five is sample of first elution.

## Discussion

Both the control and experimental SDS-PAGEs show a large amount of proteins of many sizes in the supernatant lane, which is expected as this was a sample of all of the proteins in the *E. coli*. Many of these proteins did not bind to the beads and were therefore also in the flow-through, which would also be expected because the Ni-NTA HisPur beads which were used were specific to the 6-His unique to the synthetic antibody, preventing other proteins without this tag from binding. The wash lanes indicate that there was some nonspecific binding of non-synthetic antibody proteins to the beads, which were then removed by the wash steps as the higher concentration of imidazole allowed it to competitively bind to the beads.

The elution lanes show a strong band at approximately 27 kDa, which is the predicted size of our synthetic antibody. Therefore, the antibody has essentially been purified. However, there are some remaining bands of various weights shown in the elution lanes, indicating that there is still some non-specific binding occurring, which would need to be eliminated through optimization of the protein purification protocol. This optimization would most likely involve adjustments in the wash steps, such as increasing the concentration of imidazole (increasing its ability to compete with other proteins to bind to the beads) or a greater number of washes.

## Chapter 4: Conclusion

---

### Testing & Analysis

The next steps of this project will be to analyze the functionality of the synthetic antibody. To replace the monoclonal antibody used for PSA detection, the synthetic antibody must have comparable functionality. The previous results show the experimental and control synthetic antibodies were correctly expressed. Next, the synthetic antibodies will be tested to ensure proper L-DOPA incorporation in the experimental synthetic antibody. This will be done by measuring the  $K_d$  of both synthetic antibodies to PSA using ITC. The  $K_d$  value will indicate the binding affinity between the synthetic antibody and PSA. Since the incorporation of L-DOPA allows the experimental synthetic antibody to form a covalent bond to PSA, the binding strength will be much greater than the control synthetic antibody. The values will also be compared to the binding strength of the currently used monoclonal antibody for PSA detection,  $1.1 \pm 0.2$  nM. The experimental synthetic antibody must have, at most, the same  $K_d$  value to be comparable to the anti-PSA monoclonal antibody.

Others metrics that will be tested and compared to those of the anti-PSA monoclonal antibody are specificity and sensitivity. It is crucial that the synthetic antibody is specific to PSA so that prostate cancer detection tests are precise and accurate. Both specificity and sensitivity will be tested using a Western blot. PSA samples will be titrated; then the specificity and sensitivity of the experimental synthetic antibody will be measured and compared to the anti-PSA monoclonal antibody. Currently, levels of PSA below 2.5 ng/mL are considered to be within the normal range.<sup>7</sup> Blood concentrations of PSA between 2.5 ng/mL and 4.0 ng/mL are an indication of prostate cancer.<sup>7</sup> The synthetic antibody must be able to clearly indicate the differences between these two ranges.

The design of the synthetic antibody predicts the specificity, sensitivity, and binding strength to be at least as effective, if not better than, the standards set by the currently used anti-PSA monoclonal antibody. However, these specifications must be tested to ensure incorporation of L-DOPA during expression and comparable functionality to currently used technologies.

## Summary and Future Applications

This project focuses on creating a synthetic antibody for PSA measurement for prostate cancer detection. If testing follows theoretical values, this antibody can replace the currently used anti-PSA monoclonal antibody. As previously mentioned, antibodies are used extensively in research and medicine and prostate cancer detection is just one of numerous applications. This project evaluates the synthetic antibody design as a possibility to replace other monoclonal antibodies. Synthetic antibodies avoid many of the drawbacks of monoclonal antibodies, including batch-to-batch variability, ethical concerns, and an expensive and long production process.<sup>1</sup>

The results from this project show successful design and cloning of the synthetic antibody. In addition, it was successfully produced in and purified from *E. coli*. Future testing would verify the incorporation and functionality of the synthetic antibody compared to the currently used monoclonal antibody for prostate cancer detection. This proof of concept is a model for future synthetic antibodies to be produced to essentially any other protein target. The advantages of this modular synthetic antibody design would make it desirable to researchers as well as clinicians and could become the new gold standard antibodies in industry. From the results obtained from this project, synthetic antibodies for diagnostic and therapeutic purposes are a promising technology, however, future testing is still required.

## Chapter 5: Ethical Concerns

---

Monoclonal antibodies are currently widely used in both industry and research settings, and as a result, they are an established and well-known product due to their high specificity and binding strength. However, the production process of the monoclonal antibodies has two main ethical concerns including animal use as well as the expensive nature of the process leading to concerns regarding fair access of patients to medical advancements.

The use of live animals such as mice and rabbits as a hosts of production of monoclonal antibodies is an ethical concern because it requires invoking their immune system prior to the extraction of their blood. This process is harmful to the animals and raises concerns regarding animal abuse. Overall, the use of animals as hosts for this production method is life-threatening to the animals and usually leads to their death. In comparison, synthetic antibodies do not use animals such as mice and rabbits as hosts, instead *E. coli* bacteria are used.

Another ethical concern to monoclonal antibodies is their high cost as a result of their production process. The high cost of this technology can lead to minimal access to those who cannot afford to have access to it. Monoclonal antibodies are extensively used in research for medical advancements that could benefit patients, and the high-cost can deter researchers from using it and can lead to delays in new technology. Similarly, monoclonal antibodies are used in prostate cancer blood test and their high cost increases the cost of the test. In response, health insurance companies are reluctant to pay for it if the patient does not show any signs of prostate cancer. It is necessary for these tests to be done early regardless of symptoms because the lack of early detection contributes to many cancer patient deaths.

## Chapter 6: Engineering Standards and Realistic Constraints

---

For all engineering designs, there are many considerations that must be taken into account prior to creating and implementing the design. The following factors will be discussed in terms of how the design and stakeholders that are involved will be impacted.

### **Economic**

Like any other product, economic factors are necessary to take into consideration in terms of how much resources are needed to fund as well as implement the design and the overall cost of the product for it to be used by its intended audience. For this design, it was necessary to propose a budget for funding that was enough to carry out all of the experiments. Typical antibody production requires an immense amount of resources as well as animal facilities which can drive up costs and increase the amount of labor that is needed. Instead, the synthetic antibody production is performed at a smaller scale for testing and the host that is used for production, *E. coli*, is much cheaper and easier to scale up. Not only for the practicality of this project, but for future implementation, the synthetic antibody design described in this paper is a cheaper alternative than commercial monoclonal antibody production which will benefit researchers and patients who would have increased accessibility due to the lower cost of this technology.

### **Ethical**

There are many ethical concerns with regards to who the stakeholders of this project will be. These stakeholders include who will be producing the synthetic antibody, who will be using the synthetic antibody such as researchers, academic institutions, and industry members, and lastly who would be benefitting or affected by the technology that is developed either from the indirect or direct usage of the synthetic antibody. As elaborated in Chapter 5, there are ethical concerns with regards to animal production as well as high costs that would limit the accessibility to the benefits of this technology. For this design, there are no animals used in the production process and the overall production is much cheaper than the commercial production methods currently used. As a result, this would eliminate ethical conflicts for those who are working to produce the

synthetic antibody, those who are concerned about animal mistreatment, and those who would be deterred from using antibodies due to their high costs.

A big-picture concern of this design could be if it is used as a biological weapon due to the ease of the design. The screening method could be used to screen for a peptide that can target and cause disease or a physiological disorder. Then it could be implemented and produced using the production method described in this paper in a small laboratory setting without any regulations. It is necessary to be aware of this ethical concern; however, the screening process as well as weaponizing of the synthetic antibody requires extensive knowledge that is not as straightforward as the application of the design in this paper which is to target PSA, a well-known biomarker. However engineering as well as ethical standards should be upheld by those who are producing it to cause no harm to any of the stakeholders.

## **Social**

Social responsibility towards all stakeholders is necessary to be taken into consideration for this project. Stakeholders who have limited access to the benefits of monoclonal antibody technology are those who are financially deterred as a result of high prices that would prevent insurance companies from subsidizing the cost of the application such as prostate cancer blood tests. A method that could allow for equal access to synthetic antibody is by reducing the overall cost of it. For example if the synthetic antibody is used for drug development, it would substantially reduce the cost of research due to failed attempts or multiple iterations that are required during development. This would lead to a reduced cost of the drug, and would allow for increased access to it for those who previously did not have access due to its high cost.

## **Manufacturability**

For almost all designs, it is necessary that the design is validated to work on a smaller-scale before scaling it up in order to conserve resources. However, scaling-up can lead to other challenges and complications. One of the challenges of monoclonal antibody production is that scaling-up requires larger animal facilities, and there is also a potential for variations as well as functionality in the final product due to it coming from multiple animal hosts.<sup>14</sup> This can lead to inconsistencies in quality control.<sup>14</sup>

This manufacturability concern can be overcome in the synthetic antibody design because the production platform is *E. coli* rather than multiple animal hosts. Scaling-up with *E. coli* using bioreactors has been documented in literature and has been well-studied so this design has a very real potential for scaling-up to the level of commercial usage with consistent quality.<sup>18</sup>

## **Health & Safety**

It is necessary to ensure the health and safety of not only the members of this project but also other stakeholders who would be using this product. To produce the synthetic antibody, all members of the team were qualified to work in the lab by undergoing an exam to ensure that Santa Clara University Laboratory Safety Protocol and Procedures were understood. All members have also previously worked on protein production and purification and so proper lab techniques as well as handling of hazardous material have been established, and as a result, safety in the lab for all members can be ensured.

For the stakeholders who would be using the product it is necessary that it is appropriately used for its intended purpose. An example of this would be to use the prostate specific synthetic antibody for the purpose of detection of PSA rather than for detecting another biomarker. This will ensure safety and accuracy for the patients who would be receiving the results.



## References

---

- <sup>1</sup> Lipman, Neil S., et al. "Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources." *ILAR journal* 46.3 (2005): 258-268.
- <sup>2</sup> Miersch, S., and S. S. Sidhu. "Synthetic antibodies: concepts, potential and practical considerations." *Methods* 57.4 (2012): 486-498.
- <sup>3</sup> Umeda, Aiko, et al. "A versatile approach to transform low-affinity peptides into protein probes with cotranslationally expressed chemical cross-linker." *Analytical biochemistry* 405.1 (2010): 82-88.
- <sup>4</sup> Byrne, Barry, Edwina Stack, Niamh Gilmartin, and Richard O'Kennedy. "Antibody-Based Sensors: Principles, Problems and Potential for Detection of Pathogens and Associated Toxins." *Sensors* 9.6 (2009): 4407-445.
- <sup>5</sup> Leenaars, M., & Hendriksen, C. F. M. (2005). Critical Steps in the Production of Polyclonal and Monoclonal Antibodies: Evaluation and Recommendations. *ILAR Journal*, 46(3), 269–279.
- <sup>6</sup> Key Statistics for Prostate Cancer | Prostate Cancer Facts." *American Cancer Society*. Web. 09 May 2017.
- <sup>7</sup> Katsamba, Phinikoula S., et al. "Kinetic analysis of a high-affinity antibody/antigen interaction performed by multiple Biacore users." *Analytical biochemistry* 352.2 (2006): 208-221.
- <sup>8</sup> Wals, K., & Ovaa, H. (2014). Unnatural amino acid incorporation in *E. coli*: current and future applications in the design of therapeutic proteins. *Frontiers in Chemistry*, 2, 15.
- <sup>9</sup> Hallam, Trevor J., et al. "Antibody conjugates with unnatural amino acids." *Molecular pharmaceuticals* 12.6 (2015): 1848-1862.
- <sup>10</sup> Batjargal, Solongo, Christopher R. Walters, and E. James Petersson. "Inteins as Traceless Purification Tags for Unnatural Amino Acid Proteins." *Journal of the American Chemical Society* 137.5 (2015): 1734- 1737.
- <sup>11</sup> Safar, Peter. "Alternatives to Animal Use in Research, Testing, and Education." *Journal of Neuropathology & Experimental Neurology* 48.6 (1989): 714-715.
- <sup>12</sup> Binz, H. Kaspar, Patrick Amstutz, and Andreas Plückthun. "Engineering novel binding proteins from nonimmunoglobulin domains." *Nature biotechnology* 23.10 (2005): 1257-1268.
- <sup>13</sup> Tombelli, Sara, Maria Minunni, and Marco Mascini. "Analytical applications of aptamers." *Biosensors and Bioelectronics* 20.12 (2005): 2424-2434.
- <sup>14</sup> Therriault, Jon Henry, and Thomas Evans. *Computational Design of Synthetic Antibodies for Consumer Diagnostic Tests*. Thesis. Santa Clara University, 2016.
- <sup>15</sup> Chung, C. T., Suzanne L. Niemela, and Roger H. Miller. "One-step preparation of competent *Escherichia coli*: transformation and storage of bacterial cells in the same solution." *Proceedings of the National Academy of Sciences* 86.7 (1989): 2172-2175.
- <sup>16</sup> Zhang, Zhiwen, Brian A. C. Smith, Lei Wang, Ansgar Brock, Charles Cho, and Peter G. Schultz. "A New Strategy for the Site-Specific Modification of Proteins in Vivo." *Biochemistry* 42.22 (2003): 6735-746.
- <sup>17</sup> Wang, Lei, Zhiwen Zhang, Ansgar Brock, and Peter G. Shultz. "Addition of the Keto Functional Group to the Genetic Code of *Escherichia coli*." *PNAS*. 19 Nov. 2002.
- <sup>18</sup> Rosano, Germán L., and Eduardo A. Ceccarelli. "Recombinant protein expression in *Escherichia coli*: advances and challenges." *Recombinant protein expression in microbial systems* 7 (2014).


<sup>19</sup> Tsien, Roger Y. "The Green Fluorescent Protein." *Annu. Rev. Biochem. Annual Review of Biochemistry* 67.1 (1998): 509-44.

<sup>20</sup> Bornhorst, Joshua A., and Joseph J. Falke. "[16] Purification of proteins using polyhistidine affinity tags." *Methods in enzymology* 326 (2000): 245-254.


<sup>21</sup> Drummond, D. Allan, and Claus O. Wilke. "The evolutionary consequences of erroneous protein synthesis." *Nature Reviews Genetics* 10.10 (2009): 715-724.

# Appendix

## Appendix A: pAC DHPheRS-6TRN plasmid map



## Appendix B: Experimental Vector



## Appendix C. Experimental Vector: pET28-P1+GFP+His Sequencing

### Information

LOCUS GS61233-1 pET28-P1+GFP+His 5977 bp ds-DNA circular SYN 25-Apr-2017

DEFINITION .

ACCESSION .

VERSION .

KEYWORDS GS61233-1 pET28-P1+GFP+His

SOURCE synthetic DNA construct

ORGANISM synthetic DNA construct

REFERENCE 1 (bases 1 to 5977)

AUTHORS .

TITLE Direct Submission

FEATURES Location/Qualifiers

source 1..5977

/organism="synthetic DNA construct"

/mol\_type="other DNA"

terminator 26..73

/note="T7 terminator"

/note="transcription terminator for bacteriophage T7 RNA  
polymerase"

/note="color: #ffffff"

CDS complement(140..157)

/codon\_start=1

/product="6xHis affinity tag"

/note="6xHis"

/note="color: #cc99b2"

/translation="HHHHHHH"

gene 173..949

/note="P1+GFP+His"

/note="color: #a6acb3; direction: RIGHT"

CDS complement(179..892)

/codon\_start=1

/product="GFP variant optimized for excitation by UV light"

/label="GFPuv"

/note="GFPuv"

/note="color: #05fd14"

/translation="MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLK

FICTTGKLPVPWPTLVTTFSYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDG  
 NYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNShNVYITADKQKNGIKA  
 NFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMLLE  
 FVTAAGITHGMDELYK"

protein\_bind 952..976

/bound\_moiety="lac repressor encoded by lacI"

/note="lac operator"

/note="The lac repressor binds to the lac operator to  
 inhibit transcription in E. coli. This inhibition can be  
 relieved by adding lactose or

isopropyl-beta-D-thiogalactopyranoside (IPTG)."

/note="color: #31849b"

promoter complement(977..995)

/note="T7 promoter"

/note="promoter for bacteriophage T7 RNA polymerase"

/note="color: #ffffff; direction: LEFT"

promoter 1304..1381

/gene="lacI"

/note="lacI promoter"

/note="

"

/note="color: #ffffff; direction: RIGHT"

CDS 1382..2464

/codon\_start=1

/gene="lacI"

/product="lac repressor"

/note="lacI"

/note="The lac repressor binds to the lac operator to  
 inhibit transcription in E. coli. This inhibition can be  
 relieved by adding lactose or

isopropyl-beta-D-thiogalactopyranoside (IPTG)."

/note="color: #993366"

/translation="MKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAE

LYIPNRVAQQLAGKQSLIGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGV

EACKAAVHNLLAQRVSGLIINYPLDDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSH

EDGTRLGVEHLVALGHQQIALLAGPLSSVSARLRLAGWHKYLTRNQIQPIAEREGDWSA

MSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAITESGLRVGADISVVGYYDDTEDSSC

YIPPLTTIKQDFRLLGQTSVDRLLQLSQGQAVKGNQLLPVSLVKRKTTLAPNTQTASPR  
 ALADSLMQLARQVSRLESGQ"

CDS 3273..3464

/codon\_start=1

/gene="rop"

/product="Rop protein"

/note="rop"

/note="color: #993366"

/translation="MTKQEKTALNMARFIRSQTLTLEKLNELDADEQADICESLHDHA  
 DELYRSCLARFGDDGENL"

rep\_origin complement(3894..4482)

/direction=LEFT

/note="ori"

/note="high-copy-number colE1/pMB1/pBR322/pUC origin of  
 replication"

/note="color: #ffff00"

CDS 4604..5419

/codon\_start=1

/gene="aph(3')-Ia"

/product="aminoglycoside phosphotransferase"

/note="KanR"

/note="confers resistance to kanamycin"

/note="color: #ccffcc"

/translation="MSHIQRETSCSRPRLNSNMDADLYGYKWARDNVGQSGATIYRLYG  
 KPDAPELFLKHGKGSVANDVTDEMVRNLNWLTEFMPLPTIKHFIRTPDDAWLLTTAIPGK  
 TAFQVLEEYPDSGENIVDALAVFLRRLHSIPVCNCPFNSDRVFRLAQASRMNNGLVDA  
 SDFDDERNGWPVEQVWKEMHKLLPFSPDSVVTHGDFSLDNLIFDEGKLIGCIDVGRVGI  
 ADRYQDLAILWNCLGEFSPSLQKRLFQKYGIDNPDMNKLQFHLMLDEFF"

rep\_origin complement(5511..5966)

/direction=LEFT

/note="f1 ori"

/note="f1 bacteriophage origin of replication; arrow  
 indicates direction of (+) strand synthesis"

/note="color: #ffff00"

ORIGIN

1 atccggatat agttcctcct tcagcaaaa aaccctcaa gacccgtta gaggcccaa  
 61 ggggttatgc tagttatgc tcagcgttg cagcagccaa ctacgttcc ttccggcctt

121 tgttagcagc cggatctcag tgggtggtgt ggtggtgctc gaggcgcc gcaagctttt  
181 tgttagctc atccatgcca tgtgtaatcc cagcagcagt taaaaactca agaaggacca  
241 tgtggtcagc ctttctgtt ggatctttcg aaagggcaga ttgtgtcgac aggtaatggt  
301 tgtctggtaa aaggacaggg ccatcgccaa ttggagtatt ttgtgataa tggctgcta  
361 gttgaacgga tccatcttca atgtgtggc gaattttgaa gttagctttg attcattct  
421 tttgttgc tgccgtgatg tatacattgt gtgagttata gttgtactcg agtttgtgc  
481 cgagaatgtt tccatcttct ttaaaatcaa taccttttaa ctgatacga ttaacaaggg  
541 taccacttc aaactgact tcagcagcg tcttgatgt cccgtcatct ttgaaagata  
601 tagtgcgttc ctgtacataa cttcgggca tggcactctt gaaaaagtca tgccgttca  
661 tatgatccgg ataacgggaa aagcattgaa caccataaga gaaagtagtg acaagtgtt  
721 gccatggaac aggtagttt ccagtagtgc aaataaattt aagggtagt ttccgtatg  
781 ttgcatcacc ttcacctct cactgacag aaaatttgc ccattaaca tcaccatcta  
841 attcaacaag aattgggaca actccagtga aaagtcttc tctttactc atgaattct  
901 agcaggcca gcaatgatgt tcaatgcaat acgccacgca cattctagag gggaattgtt  
961 atccgctcac aattcccta tagtgagtcg tattaattc gcgggacga gatctgac  
1021 ctctacccg gacgcatcgt ggccggcacc accggcgcca caggcggtt tctggcgcc  
1081 tatatccg acatcaccga tggggaagat cgggctgcc acttcgggct catgagcgt  
1141 tgttcggcg tgggtatggt ggcaggcccc gtggcgggg gactgttgg cgccatctcc  
1201 ttgatgcac cattcctgc ggcggcggtg ctcaacggc tcaacctact actgggctgc  
1261 ttctaatagc aggagtcga taaggagag cgtcgagatc ccggacacca tcgaatggcg  
1321 caaaacctt cgcggtatg catgatagc cccggaagag agtcaattca ggggtggtgaa  
1381 tgtgaaacca gtaacgttat acgatgtgc agagtatgcc ggtgtctct atcagaccgt  
1441 ttcccgctg gtgaaccagg ccagccagct ttctcgaaa acgcgggaaa aagtgaagc  
1501 ggcgatggcg gagctgaatt acattccaa ccgctggca caaactgg cgggcaaca  
1561 gtcgttctg attggcgtt ccacctccag tctggcctg cagcgccgt cgcaattgt  
1621 cgcgcgatt aaatctcgc ccgatcaact ggggtccagc gtggtggtg cgatgtaga  
1681 acgaagcggc gtcgaagcct gtaaagcggc ggtgcacaat cttctcgcg aacgcgtcag  
1741 tgggctgatc attactatc cgctggatga ccaggatgcc attgtgtgg aagctgcctg  
1801 cactaatgtt ccggcggtt ttctgatgt ctctgaccag acacccatca acagtattat  
1861 ttctcccat gaagacggt cgcgactggg cgtggagcat ctggtcgcat tgggtacca  
1921 gcaaatcgc ctgttagcgg gccattaag ttctgtctg gcggtctgc gctggctgg  
1981 ctggcataaa tatctactc gcaatcaat tcagccgata gcggaacggg aaggcgactg  
2041 gaggccatg tccggtttc aaaaacat gcaaatgctg aatgagggca tcttccac  
2101 tgcgatgctg gttgccaac atcagatggc gctggcgca atgcgcgcca ttaccgagtc  
2161 cgggctgcg gttggtcgg atatctcgt agtgggatac gacgataccg aagacagtc  
2221 atgttatatc ccgccgtta ccacatcaa acaggattt cgctgctgg ggcaaacag  
2281 cgtggaccgc ttgtgcaac tctctcagg ccaggcggtg aagggaac agctgttgc



2341 cgtctcactg gtgaaaagaa aaaccaccct ggcgcccaat acgcaaaccg cctctccccg  
 2401 cgcgttgcc gattcattaa tgcagctggc acgacaggtt tcccactgg aaagcgggca  
 2461 gtgagcgcaa cgcaattaat gtaagttagc tctactatta ggcaccggga tctcgaccga  
 2521 tgcccttgag agccttaac ccagtcagct cctccgggtg ggcgcggggc atgactatcg  
 2581 tcgccgcact tatgactgtc ttctttatca tgcaactcgt aggacaggtg ccggcagcgc  
 2641 tctgggtcat ttctggcgag gaccgcttc gctggagcgc gacgatgac ggctgtcgc  
 2701 ttggcggtatt cggaattctg cagccctcg ctcaagcctt cgtcactggt cccgccacca  
 2761 aacgtttcgg cgagaagcag gccattatcg ccggcatggc ggccccacgg gtgcgcatga  
 2821 tcgtgctcct gtcgttgagg acccggtag gctggcgggg ttgccttact ggtagcaga  
 2881 atgaatcacc gatacgcgag cgaacgtgaa gcgactgctg ctgcaaacg tctgcgacct  
 2941 gagcaacaac atgaatggtc ttcggttcc gtgttcgta aagtctggaa acgcggaagt  
 3001 cagcgcctcg caccattatg ttccggatct gcatcgagg atgctgctgg ctaccctgtg  
 3061 gaacacctac atctgtatta acgaagcgtt ggcattgacc ctgagtatt tttctctgt  
 3121 cccgccgat ccataccgcc agttgtttac cctcacaac ttccagtaac cgggcatggt  
 3181 catcatcagt aaccggtatc gtgagcatcc tctctgttt catcggtatc attaccccca  
 3241 tgaacagaaa tccccctac acggaggcat cagtaccaa acaggaaaa accgccctta  
 3301 acatggcccg ctttatcaga agccagacat taacgttct ggagaaactc aacgagctgg  
 3361 acgcggatga acaggcagac atctgtgaat cgcttcacga ccacgctgat gagctttacc  
 3421 gcagctgcct cgcgcgttc ggtgatgacg gtgaaaacct ctgacacatg cagctcccg  
 3481 agacggtcac agcttctctg taagcggatg ccgggagcag acaagcccg cagggcgct  
 3541 cagcgggtgt tggcgggtgt cggggcgag ccatgacca gtcacgtagc gatagcggag  
 3601 tgtatactgg cttaactatg cggcatcaga gcagattgta ctgagagtgc accatatatg  
 3661 cggtgtgaaa taccgcagag atgcgtaagg agaaaatacc gcatcaggcg ctctccgct  
 3721 tctctgctca ctgactcgt gcgctcgtc gttcggctgc ggagagcgt atcagctcac  
 3781 tcaaaggcgg taatacgggt atccacagaa tcaggggata acgcaggaaa gaacatgtga  
 3841 gcaaaaggcc agcaaaaggc caggaaacct aaaaaggccg cgttgctggc gttttccat  
 3901 aggtccgcc cccctgacga gcatcacaaa aatcgacgt caagtcagag gtggcgaaac  
 3961 ccgacaggac tataagata ccaggcgttt cccctggaa gtcctcgt gcgctcct  
 4021 gttccgacct tgccgcttac cggatactg tccgccttc tccctcggg aagcgtggcg  
 4081 ctttctcata gtcacgctg taggtatct agttcggtgt aggtcgtcg ctccaagtg  
 4141 ggctgtgtgc acgaacccc cgttcagccc gaccgctcgc cttatccgg taactatct  
 4201 cttgagtcca acccgtaag acacgactta tcgccactgg cagcagccac tggtaacagg  
 4261 attagcagag cgaggtatgt aggcggtgct acagattct tgaagtgtg gcctaactac  
 4321 ggctacacta gaaggacagt atttggtatc tgcgctctgc tgaagccagt tacctcggga  
 4381 aaaagagttg gtagctcttg atccggcaaa caaacaccg ctggtagcgg tggttttt  
 4441 gtttgcaagc agcagattac gcgcagaaaa aaaggatctc aagaagatcc ttgatctt  
 4501 tctacggggt ctgacgctca gtggaacgaa aactcaggtt aagggatttt ggtcatgaac

4561 aataaaactg tctgettaca taaacagtaa tacaaggggt gttatgagcc atattcaacg  
 4621 ggaaacgtct tctctagggc cgcgattaaa ttccaacatg gatgctgatt tatatgggta  
 4681 taaatgggct cgcgataatg tcgggcaatc aggtgcgaca atctatcgat tgtatgggaa  
 4741 gcccgatgcg ccagagttgt ttctgaaaca tggcaaaggt agcgttgcca atgatgttac  
 4801 agatgagatg gtcagactaa actggctgac ggaatttatg cctcttccga ccatcaagca  
 4861 tttatccgt actcctgatg atgcatggtt actcaccact gcgatccccg ggaaacagc  
 4921 attccaggtg ttagaagaat atcctgattc aggtgaaaat attgttgatg cgctggcagt  
 4981 gttcctgcgc cggttgcatt cgattcctgt ttgtaattgt cctttaaca gcgatgcgt  
 5041 attcgtctc gtcagggcg aatcacgaat gaataacggt ttggttgatg cgagtattt  
 5101 tgatgacgag cgtaatggct ggcctgttga acaagtctgg aaagaaatgc ataaactttt  
 5161 gccatttca ccggaattcag tcgtactca tgggtatttc tcaattgata acctatttt  
 5221 tgacaggggg aaattaatag gttgtattga tgttgacga gtcggaatcg cagaccgata  
 5281 ccaggatctt gccatctat ggaactgcct cggtagattt tctcttcat tacagaaacg  
 5341 gctttttcaa aaatatggta ttgataatcc tgatatgaat aaattgcagt ttcatttgat  
 5401 gtcgatgag ttttctaag aattaattca tgagcggata cataattgaa tgtatttaga  
 5461 aaaataaaca aatagggggt ccgcgcacat ttccccgaaa agtgccacct aaattgtaag  
 5521 cgtaaatatt ttgttaaaat tcgcgttaaa ttttgttaa atcagctcat ttttaacca  
 5581 ataggccgaa atcggcacaa tccctataa atcaaaagaa tagaccgaga taggggtgag  
 5641 tgttgttcca gtttgaaca agagtccact attaaagaac gtggactcca acgtcaaagg  
 5701 gcgaaaaacc gtctatcagg gcgatggccc actacgtgaa ccatcacctt aatcaagttt  
 5761 tttggggtcg aggtgccgta aagcactaaa tcggaaccct aaaggagacc cccgatttag  
 5821 agcttgacgg ggaaagccgg cgaactggc gagaaaggaa gggaagaaag cgaaaggagc  
 5881 gggcgctagg gcgctggcaa gtgtagcggc cagctgcgc gtaaccacca cacccgccgc  
 5941 gettaatgcg ccgctacagg gcgcgtccca ttgccca

//

## Appendix D. Control Vector: pET28-P1+GFP+His Sequencing Information

LOCUS GS61233-2 pET28-control+GFP+His 5977 bp ds-DNA circular SYN 25-Apr-2017

DEFINITION .

ACCESSION .

VERSION .

KEYWORDS GS61233-2 pET28-control+GFP+His

SOURCE synthetic DNA construct

ORGANISM synthetic DNA construct

REFERENCE 1 (bases 1 to 5977)

AUTHORS .

TITLE Direct Submission

FEATURES Location/Qualifiers

source 1..5977  
     /organism="synthetic DNA construct"  
     /mol\_type="other DNA"  
 terminator 26..73  
     /note="T7 terminator"  
     /note="transcription terminator for bacteriophage T7 RNA polymerase"  
     /note="color: #ffffff"  
 CDS complement(140..157)  
     /codon\_start=1  
     /product="6xHis affinity tag"  
     /note="6xHis"  
     /note="color: #cc99b2"  
     /translation="HHHHHH"  
 misc\_feature 173..949  
     /note="control+GFP+His"  
     /note="color: #a6acb3"  
 CDS complement(179..892)  
     /codon\_start=1  
     /product="GFP variant optimized for excitation by UV light"  
     /label="GFPuv"  
     /note="GFPuv"  
     /note="color: #05fd14"  
     /translation="MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLT  
         FICTTGKLPVPWPTLVTTFSYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDG  
         NYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNNSHNVYITADKQKNGIKA  
         NFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMLLE  
         FVTAAGITHGMDELYK"  
 protein\_bind 952..976  
     /bound\_moiety="lac repressor encoded by lacI"  
     /note="lac operator"  
     /note="The lac repressor binds to the lac operator to inhibit transcription in E. coli. This inhibition can be relieved by adding lactose or isopropyl-beta-D-thiogalactopyranoside (IPTG)."  
     /note="color: #31849b"  
 promoter complement(977..995)

```

        /note="T7 promoter"
        /note="promoter for bacteriophage T7 RNA polymerase"
        /note="color: #ffffff; direction: LEFT"
promoter      1304..1381
        /gene="lacI"
        /note="lacI promoter"
        /note="
        "
        /note="color: #ffffff; direction: RIGHT"
CDS           1382..2464
        /codon_start=1
        /gene="lacI"
        /product="lac repressor"
        /note="lacI"
        /note="The lac repressor binds to the lac operator to
        inhibit transcription in E. coli. This inhibition can be
        relieved by adding lactose or
        isopropyl-beta-D-thiogalactopyranoside (IPTG)."
```

/note="color: #993366"  
 /translation="MKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAEL  
 NYIPNRVAQQLAGKQSLIGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGV  
 EACKAAVHNLLAQRVSGLIINYPLDDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSH  
 EDGTRLGVEHLVALGHQQIALLAGPLSSVSARLRLAGWHKYLTRNQIQPIAEREGDWSA  
 MSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAITESGLRVGADISVVGYYDDTEDSSC  
 YIPPLTTIKQDFRLLGQTSVDRLLQLSQGQAVKGNQLLPVSLVKRKTTLAPNTQTASPR  
 ALADSLMQLARQVSRLESGQ"

```

CDS           3273..3464
        /codon_start=1
        /gene="rop"
        /product="Rop protein"
        /note="rop"
        /note="color: #993366"
        /translation="MTKQEKTALNMARFIRSQTLTLEKLNELDADEQADICESLHDHA
        DELYRSCLARFGDDGENL"
rep_origin    complement(3894..4482)
        /direction=LEFT
        /note="ori"

```

/note="high-copy-number colE1/pMB1/pBR322/pUC origin of  
 replication"  
 /note="color: #ffff00"  
 CDS 4604..5419  
 /codon\_start=1  
 /gene="aph(3)-Ia"  
 /product="aminoglycoside phosphotransferase"  
 /note="KanR"  
 /note="confers resistance to kanamycin"  
 /note="color: #ccffcc"  
 /translation="MSHIQRETSCSRPRLNSNMDADLYGYKWARDNVGQSGATIYRLYG  
 KPDAPELFLKHGKGSVANDVTDEMVRNLNWLTEFMPLPTIKHFIRTPDDAWLLTTAIPGK  
 TAFQVLEEYPDSGENIVDALAVFLRRLHSIPVCNCPFNSDRVFRLAQAQSRMNNGLVDA  
 SDFDDERNGWPVEQVWKEMHKLLPFSPDSVVTGDFSLDNLIFDEGKLIGCIDVGRVGI  
 ADRYQDLAILWNCLGEFSPSLQKRLFQKYGIDNPDMNKLQFHLMLDEFF"  
 rep\_origin complement(5511..5966)  
 /direction=LEFT  
 /note="f1 ori"  
 /note="f1 bacteriophage origin of replication; arrow  
 indicates direction of (+) strand synthesis"  
 /note="color: #ffff00"

## ORIGIN

1 atccggatat agttctctct ttcagcaaaa aacccctcaa gaccggtta gaggccccaa  
 61 ggggttatgc tagttattgc tcagcgggtg cagcagccaa ctgagcttc ttccgggctt  
 121 tgttagcagc cggatctcag tgggtggtgt ggtggtgctc gagtgcggcc gcaagctttt  
 181 tgtagagctc atccatgcca tgtgtaatcc cagcagcagt tacaaactca agaaggacca  
 241 tgtggtcacg ctttctgtt ggatctttcg aaagggcaga ttgtgtcgac aggtaatggt  
 301 tgtctggtaa aaggacaggg ccatcgccaa ttggagtatt ttgtgataa tggctctgta  
 361 gttgaacgga tccatcttca atgttgtggc gaattttgaa gttagctttg attcattct  
 421 tttgtttgtc tgccgtgatg tatacattgt gtgagttata gttgtactcg agtttgtgct  
 481 cgagaatggt tccatcttct ttaaaatcaa taccttttaa ctcgatacga ttaacaaggg  
 541 tatcaccttc aaacttgact tcagcacgcg tcttgtagtt cccgtcatct ttgaaagata  
 601 tagtgcgttc ctgtacataa ccttcgggca tggcactctt gaaaaagtca tgccgtttca  
 661 tatgatccgg ataacgggaa aagcattgaa caccataaga gaaagtagtg acaagtgttg  
 721 gccatggaac aggtagtttt ccagtagtgc aaataaattt aagggtgaagt ttccgtatg  
 781 ttgcatcacc ttcacctct cactgacag aaaatttggtg ccattaaca tcaccatcta  
 841 attcaacaag aattgggaca actccagtga aaagtcttc tcctttactc atgaattcgg

901 cgcaggcca gcaatgatgt tcaatgcaat acgccacgca cattctagag gggaattgtt  
 961 atccgctcac aattccccta tagtgagtcg tattaatttc gcgggatcga gatctcgatc  
 1021 ctctacgccg gacgcatcgt ggccggcacc accggcgcca caggtgcggt tgctggcgcc  
 1081 tatatcgccg acatcaccga tggggaagat cgggctcgcc acttcgggct catgagcgct  
 1141 tgttcggcg tgggtatggt ggcaggcccc gtggcgggg gactgttggg cgccatctcc  
 1201 ttgcatgcac caticcttgc ggcggcgggtg ctcaacggcc tcaacctact actgggctgc  
 1261 ttctaatgc aggagtcgca taaggagag cgtcgagatc ccggacacca tcgaatggcg  
 1321 caaaaccttt cgcggatgg catgatagcg cccggaagag agtcaattca ggggtgtgaa  
 1381 tgtgaaacca gtaacgttat acgatgtcg agagtatgcc ggtgtctctt atcagaccgt  
 1441 ttcccgctg gtgaaccagg ccagccacgt ttctcgaaa acgcgggaaa aagtggagc  
 1501 ggcatggcg gagctgaatt acattccaa ccgctggca caacaactgg cgggcaaca  
 1561 gtcgtgctg attggcgtg ccacctccag tctggccctg cacgcgccgt cgcaattgt  
 1621 cgcggcgatt aaatctcgc ccgatcaact ggggtgccagc gtggtggtgt cgatggtaga  
 1681 acgaagcggc gtcgaagcct gtaagcggc ggtgcacaat ctctcgcgc aacgcgtcag  
 1741 tgggctgac attaatatc cgctggatga ccaggatgcc attgctgtgg aagctgcctg  
 1801 cactaatgtt ccggcggtat ttctgatgt ctctgaccag acacccatca acagtattat  
 1861 ttctcccat gaagacgta cgcgactggg cgtggagcat ctggtcgcat tgggtacca  
 1921 gcaaatcgcg ctgttagcgg gccattaag ttctgtctg gcgctctgc gtctggctgg  
 1981 ctggcataaa tatctactc gcaatcaat tcagccgata gcggaacggg aaggcgactg  
 2041 gaggccatg tccggtttc aacaaacct gcaaatcgt aatgagggca tcgtccac  
 2101 tgcgatcgtg gttgccaac atcagatggc gctggcgca atgcgcgcca ttaccgagtc  
 2161 cgggctcgc gttggtcgg atatctcgg agtgggatac gacgataccg aagacagtc  
 2221 atgttatc ccgccgtta ccacatcaa acaggatgtt cgctgctgg ggcaaacag  
 2281 cgtggaccgc ttctgcaac tctctcagg ccaggcgggtg aagggaac agctgttgc  
 2341 cgtctactg gtgaaaagaa aaaccacct ggcgccaat acgcaaacg cctctccccg  
 2401 cgcgttgcc gattcattaa tgcagctggc acgacaggt tccgactgg aaagcgggca  
 2461 gtgagcgcaa cgcaattaat gtaagttagc tcaactatta ggcaccggga tctgaccga  
 2521 tgcccttag agccttaac ccagtcagct cttccgggtg ggcgcggggc atgactatg  
 2581 tcgccgact tatgactgtc ttctttatca tgcaactctg aggacaggtg ccggcagcgc  
 2641 tctgggtcat ttctggcgag gaccgcttc gctggagcgc gacgatgac ggcctgtcgc  
 2701 ttgggtatt cggaatctg cacgcctcg ctcaagcctt cgtactggt cccgccacca  
 2761 aacgtttcgg cgagaagcag gccattatc ccggcatggc ggccccacgg gtgcgcatga  
 2821 tcgtgctct gtcgtttag acccggtag gctggcgggg ttgccttact ggttagcaga  
 2881 atgaatcacc gatacgcgag cgaacgtgaa gcgactgctg ctcaaaaac tctgcacat  
 2941 gagcaacaac atgaatggtc ttgggttcc gtgttcgta aagtctggaa acgcggaagt  
 3001 cagcgccctg caccattatg ttccgatct gcacgcagg atgctgctgg ctaccctgtg  
 3061 gaacacctac atctgtatta acgaagcgtt ggcattgacc ctgagtgtt ttctctgtg

3121 cccgccgcat ccataccgcc agttgtttac cctcacaacg ttccagtaac cgggcatgtt  
3181 catcatcagt aaccggtatc gtgagcatcc tctctcggtt catcggtatc attaccccca  
3241 tgaacagaaa tcccccttac acggaggcat cagtgaccaa acaggaaaaa accgccctta  
3301 acatggcccc ctttatcaga agccagacat taacgcttct ggagaaactc aacgagctgg  
3361 acgcgggatga acaggcagac atctgtgaat cgcttcacga ccacgctgat gagctttacc  
3421 gcagctgcct cgcgcgtttc ggtgatgacg gtgaaaacct ctgacacatg cagctcccgg  
3481 agacggtcac agcttgtctg taagcggatg cggggagcag acaagcccgt cagggcgcggt  
3541 cagcgggtgt tggcgggtgt gggggcgag ccatgacca gtcacgtacg gatagcggag  
3601 tgtatactgg cttactatg cggcatcaga gcagattgta ctgagagtgc accatatatg  
3661 cggtgtgaaa taccgcacag atgcgtaagg agaaaatacc gcatcaggcg ctctccgct  
3721 tctcgtca ctgactcgt gcgctcggtc gttcggctgc ggcgagcgg atcagctcac  
3781 tcaaaggcgg taatacgggt atccacagaa tcaggggata acgcaggaaa gaacatgtga  
3841 gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggcgg cgttgctggc gttttccat  
3901 aggtccgcc cccctgacga gcatcacaaa aatcgacgct caagtcagag gtggcgaaac  
3961 ccgacaggac tataaagata ccaggcggtt cccctggaa gctccctcgt gcgctcct  
4021 gtccgacctg tccgcttac cggatactg tccgccttc tccctcggg aagcgtggcg  
4081 ctttctcata gctcacgtg taggtatctc agttcggtgt aggtcgttcg ctccaagctg  
4141 ggctgtgtgc acgaaccccc cgttcagccc gaccgtcgc cttatccgg taactatcgt  
4201 cttgagtcca acccgtaag acacgactta tcgccactgg cagcagccac tggtaacagg  
4261 attagcagag cgaggtatgt aggcgggtgct acagagtct tgaagtgggt gcctaactac  
4321 ggctacacta gaaggacagt atttggatc tgcgctctgc tgaagccagt tacctcggga  
4381 aaaagagttg gtagctcttg atccggcaaa caaaccaccg ctggtagcgg tggtttttt  
4441 gtttgcaagc agcagattac gcgcagaaaa aaaggatctc aagaagatcc ttgatcttt  
4501 tctacggggt ctgacgtca gtggaacgaa aactcacgtt aagggatttt ggtcatgaac  
4561 aataaaactg tctgttaca taaacagtaa tacaagggt gttatgagcc atattcaacg  
4621 ggaacgtct tctctagcg cgcgattaaa ttcaacatg gatgctgatt tatatgggta  
4681 taaatgggct cgcgataatg tcgggcaatc aggtgcgaca atctatcgat tgtatgggaa  
4741 gcccgatgcg ccaggttgt ttctgaaaca tggcaaagggt agcgttgcca atgatgttac  
4801 agatgagatg gtcagactaa actggctgac ggaatttatg cctctccga ccatcaagca  
4861 tttatccgt actctgatg atgcatggtt actcaccact gcgatcccc ggaaaacagc  
4921 attccaggtg ttagaagaat atctgtatc aggtgaaaat attgtgatg cgctggcagt  
4981 gttcctgcgc cggttgcatt cgattcctgt ttgtaattgt cctttaaca gcgatcgcgt  
5041 atttcgtctc gtcaggcgc aatcacgaat gaataacggt ttggtgatg cgagtattt  
5101 tgatgacgag cgtaatggct ggcctgttga acaagtctgg aaagaaatgc ataaactttt  
5161 gccattctca ccgattcag tcgtactca tggtgatttc tacttgata acctatttt  
5221 tgacgagggg aaattaatag gttgtattga tgttgacga gtcggaatcg cagaccgata  
5281 ccaggatctt gccatctat ggaactgcct cggtaggttt tctcttcat tacagaaacg

5341 gctttttcaa aaatatggta ttgataatcc tgatatgaat aaattgcagt ttcatttgat  
5401 gctc gatgag ttttctaag aattaattca tgagcggata catatttgaa tgtatttaga  
5461 aaaataaaca aataggggtt ccgcgcacat ttccccgaaa agtgccacct aaattgtaag  
5521 cgtaaatatt ttgtaaaat tcgcgttaaa ttttgtaa atcagctcat ttttaacca  
5581 ataggccgaa atcggcaaaa tccctataa atcaaaagaa tagaccgaga taggggtgag  
5641 tgttgtcca gtttgaaca agagtccact attaaagaac gtggactcca acgtcaaagg  
5701 gcgaaaaacc gtctatcagg gcgatggccc actacgtgaa ccatcacct aatcaagttt  
5761 tttgggtcg aggtgccgta aagcactaaa tcggaaccct aaaggagacc cccgatttag  
5821 agcttgacgg ggaaagccgg cgaacgtggc gagaaaggaa gggaagaaag cgaaaggagc  
5881 gggcgctagg gcgctggcaa gtgtagcggc cacgctgcgc gtaaccacca caccgccgc  
5941 gcttaatgcg ccgtacagg gcgcgtccca ttcgcca

//



## Appendix E. Cloning Reactions

**Table 1. Sample Klenow Extension Reaction.**

	<b>Reaction 1 (P1+TAG)</b>	<b>Reaction 2 (P1+GCG)</b>
Klenow (NEB M0210S 2015)	0.5 µL	0.5 µL
Oligo 1 (F)	1 µL (1.36 µg)	1 µL (1.36 µg)
Oligo 2 (R)	1 µL (1.36 µg)	1 µL (1.36 µg)
10X NEB 2 Buffer (2016)	2.0 µL	2.0 µL
dNTPs (Promega 12/17)	6.6 µL	6.6 µL
ddH <sub>2</sub> O	8.85 µL	8.85 µL
<b>Total Reaction Volume</b>	20 µL	20 µL
Add EDTA (0.5M stock)	0.4 µL	0.4 µL

\*Incubate reaction for 15 mins at 25°C

\*\*End reaction by adding 0.4 µL of 0.5M EDTA and heating at 75°C for 20 minutes

**Table 2. Sample Insert Double Digestion Reaction.**

DNA (insert, 1µg)	10 µL
10X NEB Buffer	5 µL
Restriction Enzyme 1: EcoRI-HF	1 µL
Restriction Enzyme 2: XbaI	1 µL
ddH <sub>2</sub> O	33 µL
<b>Total Reaction Volume</b>	50 µL

\*Incubate reaction for 10 hours at 37°C.

**Table 3. Sample pET28b-GFP Double Digestion Reaction.**

DNA (pET28b-GFP, 1 µg)	10 µL
Restriction Enzyme 1: EcoRI-HF	1 µL
Restriction Enzyme 2: XbaI	1 µL
10X NEB Buffer	5 µL
ddH <sub>2</sub> O	33 µL
<b>Total Reaction Volume</b>	50 µL

\*Incubate reaction for 4 hours at 37°C.

**Table 4. Sample Calf Intestinal Alkaline Phosphatase (CIP) Reaction for pET28b-GFP.**

DNA (pET28b-GFP, 1 µg)	15 µL
10X Cutsmart Buffer	2 µL
CIP	0.5 µ
ddH <sub>2</sub> O	2.5 µL
<b>Total Reaction Volume</b>	20 µL

\*Incubate reaction for 50 minutes at 37°C.

**Table 5. Sample pET28b-GFP + Oligonucleotide Ligation Reaction.**

pET28b-GFP (47.5 ng)	5 µL
Oligonucleotide (4.82 ng)	3.2 µL
T4 DNA Ligase	1 µL
T4 DNA Ligase Buffer	1 µL
<b>Total Reaction Volume</b>	10.2 µL

\*Incubate reaction for 4 hours at 23°C

\*\* Reaction shown is 1:10 pET28b-GFP:oligonucleotide. 1:1 and 1:2 reactions were also performed.

## Appendix F. Project Expenses

Product	Cost
Sequencing	\$156
L-arabinose	\$61
Oligonucleotides	\$118.12
L-DOPA	\$51.90
Cloning	\$535
<b>Total</b>	<b>\$922.02</b>

## Appendix G. Project Timeline




Figure 4. Project Timeline.